Literature DB >> 18600386

Comparison of short- and long-term treatment protocols and the results of second-line quadruple therapy in children with Helicobacter pylori infection.

Yusuf Usta1, Inci Nur Saltik-Temizel, Hulya Demir, Nuray Uslu, Hasan Ozen, Figen Gurakan, Aysel Yuce.   

Abstract

BACKGROUND: Research regarding the optimal therapeutic approach to Helicobacter pylori infection in children is ongoing. There is no consensus as to duration of treatment or second-line therapy. The purpose of this study was compare the efficacy of 7-day and 14-day triple therapies and report the results of second-line quadruple therapy in children.
METHODS: A total of 275 consecutive H. pylori-infected patients were enrolled into two groups. Group 1 (n = 180) received triple therapy with 14 days of amoxicillin and clarithromycin and 21 days of proton pump inhibitor. Group 2 (n = 95) received triple therapy including 7 days of amoxicillin and clarithromycin with 21 days of proton pump inhibitor. Subsequently, 89 patients not responding to the triple therapies received quadruple therapy comprising omeprazole (14 days), bismuth subcitrate (7 days), doxycycline (7 days), and metronidazole (7 days). Eradication was evaluated by 13C-urea breath test.
RESULTS: The per-protocol eradication rates in groups 1 and 2 were 60.5% and 55.8%, respectively (P = 0.44). In the second interview with 227 patients, severe symptoms were reported to have disappeared in 59% and decreased notably in 34.8%. Helicobacter pylori was eradicated in 66.7% of patients at the end of the quadruple therapy. In the third interview with 75 patients, severe symptoms had decreased in 38.6% and disappeared in 56%.
CONCLUSIONS: The different duration of the two treatment regimens had no impact on eradication rates. Furthermore, quadruple therapy was necessary to achieve H. pylori eradication after triple therapy. However, the eradication rate with quadruple therapy was still insufficient. Consequently, a new therapeutic approach to H. pylori infection in children is needed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18600386     DOI: 10.1007/s00535-008-2187-4

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  29 in total

1.  A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection.

Authors:  X Calvet; N García; T López; J P Gisbert; E Gené; M Roque
Journal:  Aliment Pharmacol Ther       Date:  2000-05       Impact factor: 8.171

2.  Helicobacter pylori infection in children: recommendations for diagnosis and treatment.

Authors:  B D Gold; R B Colletti; M Abbott; S J Czinn; Y Elitsur; E Hassall; C Macarthur; J Snyder; P M Sherman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2000-11       Impact factor: 2.839

3.  Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis.

Authors:  E Gené; X Calvet; R Azagra; J P Gisbert
Journal:  Aliment Pharmacol Ther       Date:  2003-05-01       Impact factor: 8.171

4.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.

Authors:  P Malfertheiner; F Megraud; C O'Morain; F Bazzoli; E El-Omar; D Graham; R Hunt; T Rokkas; N Vakil; E J Kuipers
Journal:  Gut       Date:  2006-12-14       Impact factor: 23.059

5.  Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study.

Authors:  Rocco Maurizio Zagari; Gabriele Bianchi-Porro; Roberto Fiocca; Giovanni Gasbarrini; Enrico Roda; Franco Bazzoli
Journal:  Gut       Date:  2006-10-06       Impact factor: 23.059

6.  Comparison of amoxicillin-metronidazole plus famotidine or lansoprazole for amoxicillin-clarithromycin-proton pump inhibitor treatment failures for Helicobacter pylori infection.

Authors:  Kazunari Murakami; Tadayoshi Okimoto; Masaaki Kodama; Ryugo Sato; Hajime Miyajima; Masami Ono; Kunimitsu Inoue; Koichiro Watanabe; Satoshi Otsu; Toshio Fujioka
Journal:  Helicobacter       Date:  2006-10       Impact factor: 5.753

Review 7.  Treatment of Helicobacter pylori infection.

Authors:  Lucas G Cavallaro; Brian Egan; Colm O'Morain; Francesco Di Mario
Journal:  Helicobacter       Date:  2006-10       Impact factor: 5.753

8.  A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy.

Authors:  N Magaret; M Burm; D Faigel; C Kelly; W Peterson; M B Fennerty
Journal:  Dig Dis       Date:  2001       Impact factor: 2.404

Review 9.  Treatment of Helicobacter pylori.

Authors:  K Wolle; P Malfertheiner
Journal:  Best Pract Res Clin Gastroenterol       Date:  2007       Impact factor: 3.043

Review 10.  Update on Helicobacter pylori treatment.

Authors:  Adrienne Z Ables; I Simon; Emily R Melton
Journal:  Am Fam Physician       Date:  2007-02-01       Impact factor: 3.292

View more
  5 in total

1.  Second-line rescue therapy of helicobacter pylori infection.

Authors:  Javier P Gisbert
Journal:  Therap Adv Gastroenterol       Date:  2009-11       Impact factor: 4.409

2.  Bismuth salts in the treatment of Helicobacter pylori infection in children.

Authors:  Selim Gökçe
Journal:  Dig Dis Sci       Date:  2010-02       Impact factor: 3.199

3.  Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection.

Authors:  J P Gisbert; A Perez-Aisa; L Rodrigo; J Molina-Infante; I Modolell; F Bermejo; M Castro-Fernández; R Antón; B Sacristán; A Cosme; J Barrio; Y Harb; M Gonzalez-Barcenas; M Fernandez-Bermejo; A Algaba; A C Marín; A G McNicholl
Journal:  Dig Dis Sci       Date:  2013-10-15       Impact factor: 3.199

Review 4.  Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance.

Authors:  Javier Molina-Infante; Javier P Gisbert
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

5.  Rescue Therapy for Helicobacter pylori Infection 2012.

Authors:  Javier P Gisbert
Journal:  Gastroenterol Res Pract       Date:  2012-02-28       Impact factor: 2.260

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.